1.80
-0.03 (-1.64%)
| Previous Close | 1.83 |
| Open | 1.84 |
| Volume | 25,500 |
| Avg. Volume (3M) | 218,090 |
| Market Cap | 929,829,568 |
| Price / Sales | 57.53 |
| Price / Book | 0.800 |
| 52 Weeks Range | |
| Earnings Date | 25 Mar 2025 - 31 Mar 2025 |
| Operating Margin (TTM) | -835.00% |
| Diluted EPS (TTM) | -1.10 |
| Total Debt/Equity (MRQ) | 0.30% |
| Current Ratio (MRQ) | 5.76 |
| Operating Cash Flow (TTM) | -341.66 M |
| Levered Free Cash Flow (TTM) | -182.32 M |
| Return on Assets (TTM) | -18.12% |
| Return on Equity (TTM) | -40.05% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (HK) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | GENOR-B | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | -0.13 |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| GENOR-B | 930 M | - | - | 0.800 |
| LEPU BIO-B | 5 B | - | - | 4.75 |
| FRONTAGE | 3 B | - | 83.00 | 1.29 |
| ALPHAMAB-B | 3 B | - | - | 1.88 |
| ABBISKO-B | 3 B | - | - | 1.21 |
| CSTONE PHARMA-B | 3 B | - | - | 5.94 |
|
Genor Biopharma Holdings Ltd is a commercial-ready biopharmaceutical company focusing on developing and commercializing oncology and autoimmune drugs. The company is focused on therapeutic areas with substantial unmet medical needs in oncology, autoimmune, and other chronic diseases. Its key drug candidates include GB491 (lerociclib), a differentiated oral CDK4/6 inhibitor; GB221, a novel HER2 mAb drug candidate; geptanolimab (GB226), GB492, a STING agonist expected to exert synergistic effects in combination with GB226; GB242, an infliximab (Remicade) biosimilar; and GB223, a RANKL, and others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 8.62% |
| % Held by Institutions | 30.58% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |